Medical Patent News RSS Feed - Medical Patent News

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. [More]
Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

A Skidmore College alumnus and professor have been awarded U.S. Patent No. 8,598,150 for use of an antioxidant compound that shows promise in the treatment of obesity and related disorders, such as type-2 diabetes. [More]

USPTO rejects NIKKEN's effort to invalidate Imagenetix's patent

Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent. [More]
GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma. [More]
‘Statistical Model for Predicting Falling in Humans’ algorithm awarded US patent

‘Statistical Model for Predicting Falling in Humans’ algorithm awarded US patent

Each year, one in every three adults age 65 and older falls, according to the Centers for Disease Control (CDC). These falls are the leading cause of fatal and nonfatal injuries among older adults, resulting in approximately $30 billion in direct medical costs per year. [More]

NSU scientist awarded U.S. patent to develop fall prevention model

Each year, one in every three adults age 65 and older falls, according to the Centers for Disease Control (CDC). These falls are the leading cause of fatal and nonfatal injuries among older adults, resulting in approximately $30 billion in direct medical costs per year. [More]

USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery. [More]
Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes. [More]
European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

22nd Century Group, Inc. today announced that the European Patent Office issued a Notice of Grant to the company for the NBB and A622 genes. Both genes are responsible for nicotine production in the tobacco plant. [More]

Neovasc's Tiara transcatheter mitral valve replacement technology gets US patent

Neovasc Inc. today announced that the first patent covering the company's innovative Tiara transcatheter mitral valve replacement technology has been issued by the US Patent and Trademark Office. [More]

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International AB today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T. [More]
Patrys gets second US patent for anti-cancer product PAT-LM1

Patrys gets second US patent for anti-cancer product PAT-LM1

Patrys Limited, a clinical stage biotechnology company is pleased to advise that it has been granted a second US patent for lead anti-cancer product PAT-LM1. [More]
IUSL awarded patent for method for changing perception of skin tone

IUSL awarded patent for method for changing perception of skin tone

​How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations. [More]
VG Life Sciences' peptide awarded US patent for HIV treatment

VG Life Sciences' peptide awarded US patent for HIV treatment

The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection. [More]

Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Sanovas Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office issued patent # 8,540,667 for the company's Multi-Balloon Catheter for Extravasated Drug Delivery. [More]
3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). [More]

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB). [More]
OrbusNeich Medical settles all stent-related litigation with Boston Scientific

OrbusNeich Medical settles all stent-related litigation with Boston Scientific

OrbusNeich Medical Inc. and Boston Scientific Corporation have settled all stent-related litigation between the companies. [More]
LifeSensors receives U.S. patent for development of novel DUB substrates

LifeSensors receives U.S. patent for development of novel DUB substrates

LifeSensors, Inc., a biotech company developing cutting-edge technologies for studying the ubiquitin pathway, has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase substrates (US 8,518,660). [More]
Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules. [More]